TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05941286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM system with only glucose threshold alerts on
Description: the cloud-based real-time continuous glucose monitoring and management system with only glucose threshold alerts on

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CGM system with glucose alerts off
Description: the cloud-based real-time continuous glucose monitoring and management system with glucose predictive/threshold alerts off
Study: NCT05579652

Intervention type: DIAGNOSTIC_TEST
Intervention: Abdominal tension measurement
Description: A tensiometer scale will be used to measure the tension needed to pull each side of the abdominal wall to midline
Study: NCT06102811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Concentration Local Anesthetic Fascia Iliaca Compartment Block
Description: Fascia iliaca block with Ropivacaine 0.075% (50 mL)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Concentration Local Anesthetic Fascia Iliaca Compartment Block
Description: Fascia iliaca block with Ropivacaine 0.25% (50 mL)
Study: NCT05590156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Rehabilitation (ExoRehab X)
Description: Robotic Rehabilitation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Action Observation Therapy (AOT)
Description: Action Observation Therapy (AOT)
Study: NCT04904159

Intervention type: PROCEDURE
Intervention: Thyroidectomy
Description: total thyroidectomy

Intervention type: PROCEDURE
Intervention: Lobectomy
Description: Lobectomy
Study: NCT04103983

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensory retraining device
Description: All participants will be given a device to keep at home and will be asked to use it for 60 minutes each day, as one block, or as multiple shorter sessions of 20 minutes minimum duration. Participants will be asked to use their device on 15 of the 21 days. They will be asked to spread out the use of the device over the 21 days. Participants are asked to record device use in a diary.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensory retraining device
Description: All participants will be given a device to keep at home and will be asked to use it for 60 minutes each day, as one block, or as multiple shorter sessions of 20 minutes minimum duration. Participants will be asked to use their device on 15 of the 21 days. They will be asked to spread out the use of the device over the 21 days. Participants are asked to record device use in a diary.
Study: NCT05605041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Headspace
Description: Headspace is an app that allows users to practice mindfulness through guided meditation
Study: NCT04614116

Intervention type: OTHER
Group type: OTHER
Intervention: External cooling
Description: water-circulating cooling/warming sleeves connected to a medical cooling device (Hilotherm Clinic®, Hilotherm GmbH, Germany) will be placed around the subject's abdomen and lower back. Initially the temperature of the water will be set to 25°C. A mild cold stimulus will be applied by reducing the temperature of the circulating water by approximately 1°C every 2 minutes to a minimum of 10°C.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FDG PET/CT
Description: o 75 MBq 18F-FDG will be injected through the intravenous line on the scanner manually (bolus injection) with a simultaneous start of dynamic FDG-PET/CT scan for 45 minutes and a partial body scan from head to the abdomen after 45 minutes. Total scan time 60 minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FDG PET/CT
Description: o 75 MBq 18F-FDG will be injected through the intravenous line on the scanner manually (bolus injection) with a simultaneous start of dynamic FDG-PET/CT scan for 45 minutes and a partial body scan from head to the abdomen after 45 minutes. Total scan time 60 minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 13C-Glucose injection
Description: 0.5 g 13C-Glucose i.v. infusion over 5 minutes, after termination of FDG injection

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 13C-Glucose injection
Description: 0.5 g 13C-Glucose i.v. infusion over 5 minutes, after termination of FDG injection
Study: NCT06273085

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: 3 sessions of education over phone at 1, 3 and 5 months after discharge, each session includes an overview of benefits and side effects of GDMT, inquiries about reasons of not using optimal doses of GDMT medications, and encouraging adherence to visits with providers.
Study: NCT06314009

Intervention type: DIAGNOSTIC_TEST
Intervention: functional Magnetic Resonance Imaging (fMRI)
Description: Participants will undergo a functional Magnetic Resonance Imaging (fMRI) using arterial spin labeling (ASL) and other Magnetic Resonance (MR) sequences

Intervention type: DIAGNOSTIC_TEST
Intervention: functional Magnetic Resonance Imaging (fMRI)
Description: Participants will undergo a functional Magnetic Resonance Imaging (fMRI) using arterial spin labeling (ASL) and other Magnetic Resonance (MR) sequences
Study: NCT05246176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nephrostomy set
Description: insertion of the nephrostomy set through the skin to obtaining good external drainage of bile in case of malignant obstructive jaundice.
Study: NCT04711967

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: fecal microbiota transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: drug
Description: drug
Study: NCT05012865

Intervention type: DRUG
Intervention: avelumab
Description: as provided in real world practice

Intervention type: DRUG
Intervention: axitinib
Description: as provided in real world practice
Study: NCT04882865

Intervention type: DEVICE
Intervention: assist
Description: A custom designed patient wrap will envelope the patient. This will be coupled to a mechanical lift system to facilitate repositioning of the patient (AMMP) Commercially available repositioning sheets will be used for the general care of some study patients

Intervention type: DEVICE
Intervention: assist
Description: A custom designed patient wrap will envelope the patient. This will be coupled to a mechanical lift system to facilitate repositioning of the patient (AMMP) Commercially available repositioning sheets will be used for the general care of some study patients
Study: NCT04961099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY01
Description: low-dose group: HY01 10mg（20mg/ml）, administrated on D1, D4 and D7 high-dose group: HY01 20mg（40mg/ml）, administrated on D1, D4 and D7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY01
Description: low-dose group: HY01 10mg（20mg/ml）, administrated on D1, D4 and D7 high-dose group: HY01 20mg（40mg/ml）, administrated on D1, D4 and D7
Study: NCT06248905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation program based on the strengthening of gluteal muscles
Description: Physiotherapy program (8 weeks)
Study: NCT04882865

Intervention type: DEVICE
Intervention: assist
Description: A custom designed patient wrap will envelope the patient. This will be coupled to a mechanical lift system to facilitate repositioning of the patient (AMMP) Commercially available repositioning sheets will be used for the general care of some study patients
Study: NCT05623631

Intervention type: OTHER
Group type: OTHER
Intervention: Survey
Description: Surveys were distributed using REDCap, and participants were asked to complete these within 5 weeks of receiving the invitation.
Study: NCT04928534

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests, Cognitive function tests, head MRI (plain scan and DTI sequence) examination and head PET (FDG-PET, Tau-PET and Amyloid-PET) examination
Description: 1. Blood tests (30-ml venous blood) for the following items. 1) Transcriptomics and proteomics high-throughput detection and quantitative verification; 2) Exosomal transcriptomics and proteomics high-throughput detection and quantitative verification; 3) Quantitative detection for classical biomarkers of traumatic brain injury, including S100B, GFAP, UCH-L1, NFL, T-Tau and p-Tau181.~2. Cognitive function tests, including RPQ, MMSE and MoCA.~3. Possible head MRI (plain scan and DTI sequence) examination and head PET (FDG-PET, Tau-PET and Amyloid-PET) examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests, Cognitive function tests, head MRI (plain scan and DTI sequence) examination and head PET (FDG-PET, Tau-PET and Amyloid-PET) examination
Description: 1. Blood tests (30-ml venous blood) for the following items. 1) Transcriptomics and proteomics high-throughput detection and quantitative verification; 2) Exosomal transcriptomics and proteomics high-throughput detection and quantitative verification; 3) Quantitative detection for classical biomarkers of traumatic brain injury, including S100B, GFAP, UCH-L1, NFL, T-Tau and p-Tau181.~2. Cognitive function tests, including RPQ, MMSE and MoCA.~3. Possible head MRI (plain scan and DTI sequence) examination and head PET (FDG-PET, Tau-PET and Amyloid-PET) examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests, Cognitive function tests, head MRI (plain scan and DTI sequence) examination and head PET (FDG-PET, Tau-PET and Amyloid-PET) examination
Description: 1. Blood tests (30-ml venous blood) for the following items. 1) Transcriptomics and proteomics high-throughput detection and quantitative verification; 2) Exosomal transcriptomics and proteomics high-throughput detection and quantitative verification; 3) Quantitative detection for classical biomarkers of traumatic brain injury, including S100B, GFAP, UCH-L1, NFL, T-Tau and p-Tau181.~2. Cognitive function tests, including RPQ, MMSE and MoCA.~3. Possible head MRI (plain scan and DTI sequence) examination and head PET (FDG-PET, Tau-PET and Amyloid-PET) examination
Study: NCT06248905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Description: Focused shock wave therapy (3 weeks)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock wave therapy
Description: Focused shock wave therapy (3 weeks)
Study: NCT05596994

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lighting Intervention Therapy
Description: The LIT will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. The TLI intervention will remain in place and will be delivered to participants for 10 weeks each in a counterbalanced manner. Combining spectrum and light level, LIT will allow the research team to: (a) use a light source that will stimulate the circadian system, and (b) provide the participants with options as to how the light treatment will be delivered. The research team will deliver at least 300-400 lux at the eye of the bluish-white light during the day (CS of 0.4 or greater) and about 50 lux at the eye during the evening hours (CS of less than 0.1) and when the control lighting intervention is used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lighting Intervention Therapy
Description: The LIT will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. The TLI intervention will remain in place and will be delivered to participants for 10 weeks each in a counterbalanced manner. Combining spectrum and light level, LIT will allow the research team to: (a) use a light source that will stimulate the circadian system, and (b) provide the participants with options as to how the light treatment will be delivered. The research team will deliver at least 300-400 lux at the eye of the bluish-white light during the day (CS of 0.4 or greater) and about 50 lux at the eye during the evening hours (CS of less than 0.1) and when the control lighting intervention is used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham LIT
Description: A placebo comparison lighting intervention will be used. The comparison lighting intervention will remain in place and will be delivered to participants for 10 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham LIT
Description: A placebo comparison lighting intervention will be used. The comparison lighting intervention will remain in place and will be delivered to participants for 10 weeks.
Study: NCT05372588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVX-CoV2515
Description: Intramuscular (deltoid) injection of co-formulated Omicron BA.1 SARS-CoV-2 rS vaccine with Matrix-M adjuvant (0.5 mL).
Study: NCT05405036

Intervention type: OTHER
Intervention: simulated patient
Description: In the last month of the Measurement and Evaluation course in Physiotherapy, a simulated patient session will be held four times (with disease in the cervical-lumbar-shoulder and knee region). Students will be evaluated by the methods they learned about patients. 10 days before and after the simulated patient sessions, the questionnaire will be applied in Turkish for validity and reliability, and then the questionnaire will be repeated after the simulated patient sessions are over, and the effect of the smile patient sessions on the perceived communication skills of the patient will be examined.
Study: NCT04586244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: retifanlimab
Description: retifanlimab will be administered via IV over 30 minutes (+ 15 min) on Day 1 of each 28-day cycle, up to 3 cycles,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: retifanlimab
Description: retifanlimab will be administered via IV over 30 minutes (+ 15 min) on Day 1 of each 28-day cycle, up to 3 cycles,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: retifanlimab
Description: retifanlimab will be administered via IV over 30 minutes (+ 15 min) on Day 1 of each 28-day cycle, up to 3 cycles,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: retifanlimab
Description: retifanlimab will be administered via IV over 30 minutes (+ 15 min) on Day 1 of each 28-day cycle, up to 3 cycles,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epacadostat
Description: epacadostat will be administered daily twice daily orally up to and including day of surgery.
Study: NCT05905263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application group with virtual reality
Description: Each student will be introduced to the materials to be used for virtual reality and will be informed about the application. After the introduction and information is given, the lens and pupil distances of the virtual reality glasses will be adjusted according to each student and students will be asked to wear them on their heads. Students will then be required to wear gloves. The application will be made one-on-one with each student. The application will be carried out sitting in the laboratory. If the student experiences symptoms such as dizziness and nausea during the application, the application will be terminated. If the student wants to continue the practice after listening, it will be continued. While the students are inside the application, the interface will be introduced through the images projected to the computer simultaneously.
Study: NCT04586244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epacadostat
Description: epacadostat will be administered daily twice daily orally up to and including day of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02385
Description: INCAGN02385 will be administered via IV over 30 minutes (-5/+10 min) every 2 weeks.
Study: NCT05372588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVX-CoV2515
Description: Intramuscular (deltoid) injection of co-formulated Omicron BA.1 SARS-CoV-2 rS vaccine with Matrix-M adjuvant (0.5 mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVX-Cov2373
Description: Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVX-Cov2373
Description: Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVX-Cov2373
Description: Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).
Study: NCT04871516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Boost
Description: Undergo radiation therapy boost

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Surgical Procedure
Description: Undergo standard surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Breast Irradiation
Description: Undergo standard WBI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast MRI
Description: A baseline breast MRI
Study: NCT05372588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 + NVX-CoV2515
Description: Intramuscular (deltoid) injection of 5 µg total (2.5 µg NVX-CoV2373 + 2.5 µg NVX-CoV2515) with 50 µg Matrix-M adjuvant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVX-CoV2540
Description: Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).
Study: NCT06104631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BK003
Description: The product is a combination of chitin-glucan and other dietary complement components. The dosage of chitin-glucan is 3 g/day. The product is a powder for oral administration 1x/day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product has the same composition in excipient, same form and same posology as BK003.
Study: NCT05440630

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Participants in this arm will receive a daily dose of 1x10\^10 Colony Forming Unit (CFU) of a single strain probiotic (live bacteria) for 16 weeks.
Study: NCT05372588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 + NVX-CoV2540
Description: Intramuscular (deltoid) injection of 5 µg total (2.5 µg NVX-CoV2373 + 2.5 µg NVX-CoV2515) with 50 µg Matrix-M adjuvant.
Study: NCT04958343

Intervention type: PROCEDURE
Intervention: pelvic reconstruction
Description: After radical cystectomy, the pelvic reconstruction including the ligation of dorsal vascular complex and posterior reconstruction will be performed on patients.
Study: NCT05440630

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postbiotic
Description: Participants in this arm will receive a daily dose of 1x10\^10 Colony Forming Unit (CFU) of a single strain postbiotic (Heat treated bacteria) for 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this arm will receive an equivalent placebo for 16 weeks.
Study: NCT05660031

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LHB Tenotomy
Description: Will be performed arthroscopically by cutting the LHB at its origin with arthroscopic scissors

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LHB Tenodesis
Description: ill be performed arthroscopically with a tenodesis at the top of the articular margin using an onlay technique.
Study: NCT05858073

Intervention type: OTHER
Group type: OTHER
Intervention: Kinesio Taping
Description: Standard 5 cm Kinesio Tex will be used. Initially, a Y-strip was paper-off (without tension) from the starting point to the insertion of the supraspinatus, while the participants were reaching with their upper extremities behind their backs and flexing their necks to the contralateral side. Second, an I-strip from the coracoid process will be applied around the posterior deltoid using approximately 50% to 75% downward flexion. Initially, the shoulder will be externally rotated without elevation, and then slightly horizontally adduction and forward elevation as the end of the band is applied without stretching. This I strip is shaped like a Y at the end of the tape.~Finally, a Y-strip will be applied using paper-off tension from the T10-T12 region to the medial border of the scapula to facilitate the lower trapezius muscle. For this technique, the shoulder was adducted horizontally and the middle tail was applied with the hands crossed over the chest.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Kinesio Taping
Description: Standard placebo taping will be applied to the placebo Kinesio taping group with a standard 5 cm Kinesio Tex. Two tension-free strips will be applied separately to the acromioclavicular joint and lower trapezius muscle. Suspicious participants will be excluded from the study.
Study: NCT06242041

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium zirconium cyclic silicate
Description: On the non-dialysis day, the drug was given to patients in the treatment group, four times a week, starting from 5g/day each time, and the blood potassium before dialysis was maintained at 4.0-5.0mmol/L, which could be adjusted at 10g/week each time, and the highest dose could be increased to 80g/ week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium zirconium cyclic silicate
Description: On the non-dialysis day, the drug was given to patients in the treatment group, four times a week, starting from 5g/day each time, and the blood potassium before dialysis was maintained at 4.0-5.0mmol/L, which could be adjusted at 10g/week each time, and the highest dose could be increased to 80g/ week.
Study: NCT04586244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02385
Description: INCAGN02385 will be administered via IV over 30 minutes (-5/+10 min) every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02390
Description: INCAGN02390 will be administered via IV over 30 minutes (-5/+10 min) every 2 weeks.